Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

33.23
-0.7099-2.09%
Volume:286.04K
Turnover:9.65M
Market Cap:4.25B
PE:-23.22
High:34.21
Open:34.21
Low:32.97
Close:33.94
52wk High:41.14
52wk Low:10.83
Shares:128.00M
Float Shares:112.00M
Volume Ratio:0.51
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4309
EPS(LYR):-1.5305
ROE:-74.73%
ROA:-44.13%
PB:17.78
PE(LYR):-21.71

Loading ...

OverviewCompanyNewsFilings

Under the Radar: Amylyx Stock Surges on Positive Trial Results

Dow Jones
·
Aug 18

Top Midday Stories: Home Depot Q2 EPS, Revenue Top Estimates; Klarna Cuts Guidance, Plans CFO, CMO Transitions

MT Newswires Live
·
Aug 18

Shares of Amylyx Pharmaceuticals Surge Nearly 51% as Key Trial Meets Main Goal

Stock News
·
Aug 18

Amylyx Soars as Blood Sugar Drug Succeeds in Late-Stage Trial

Reuters
·
Aug 18

Amylyx Shares Jump 45% Following Positive Phase 3 Trial Results for GLP-1 Blocker Avexitide

TIPRANKS
·
Aug 18

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Insight Molecular Diagnostics (IMDX) and Innovent Biologics (OtherIVBXF)

TIPRANKS
·
Aug 18

Stifel views Amylyx data as ‘best-case scenario’

TIPRANKS
·
Aug 18

Amylyx Phase 3 data support FDA approval, says Citi

TIPRANKS
·
Aug 18

Amylyx rises 41.7%

TIPRANKS
·
Aug 18

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday

MT Newswires Live
·
Aug 18

Amylyx up 28% at $27.50 after announcing Lucidity trial met primary endpoint

TIPRANKS
·
Aug 18

Amylyx Shares up 29.7% Premarket After Co Says Its Drug Cuts Low Blood Sugar Episodes in Bariatric Surgery Patients in Key Trial

THOMSON REUTERS
·
Aug 18

Amylyx Stock Surges 42% After GLP-1 Drug Succeeds in Phase 3 Trial

Dow Jones
·
Aug 18

Amylyx Says FDA Grants Avexitide Breakthrough Therapy, Orphan Drug Status for Post-Bariatric Hypoglycemia

Reuters
·
Aug 18

Amylyx announces Lucidity Phase 3 trial met primary endpoint

TIPRANKS
·
Aug 18

Amylyx Pharmaceuticals: Lucidity Met FDA-Agreed-upon Primary Endpoint and All Secondary Endpoints

THOMSON REUTERS
·
Aug 18

Amylyx: Plans to Submit Nda for Avexitide with FDA by Year-End & Plans for Potential Launch in 2027, if Approved

THOMSON REUTERS
·
Aug 18

Amylyx Pharmaceuticals, - Lucidity Meets All Secondary Endpoints with Significant Reductions in Hypoglycemic Events

THOMSON REUTERS
·
Aug 18

Amylyx Pharmaceuticals, - Avexitide Generally Well-Tolerated with Favorable Safety Profile

THOMSON REUTERS
·
Aug 18

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Aug 18
More